Fig. 2.

Effects of zoledronate therapy for 14 weeks on long bones and serum chemistries. A: BMD of the trabecular and cortical bone of the femur was determined at the 20% and 50% position, respectively, of the bone length from the proximal end using pQCT. B: Bone area (%) was measured histomorphometrically in the proximal tibiae. C: The ratio of the number of empty osteocyte lacunae to the total number of osteocyte lacunae was calculated in the cortex of the proximal tibiae. No significant increase or decrease in zoledronate-treated rats was noted when compared to control. D: Mean serum TRAcP5b levels were determined every 4 weeks. The serum TRAcP5b levels were significantly lower in ZA and HZA rats than control. E: Osteoclast numbers per linear perimeter in the proximal tibiae were significantly less in HZA and ZA rats than controls. F: Mean serum calcium levels were measured at day-0 and week-12. Significant reduction was observed in HZA rats. G: Intact PTH levels were measured in the week-12 serum. H: Serum P1NP levels were assessed at week-12. Significant decrease was found in ZA rats compare to control. All data represent mean ± SE, n=8/group. One-way ANOVA was used for the statistical analysis except for serum calcium (paired samples t-test). *p < 0.05, **p < 0.01, ***p < 0.001.